OverviewSuggest Edit

Knight Therapeutics is a specialty pharmaceutical company focused on acquiring, in-licensing, selling, and marketing prescription and over-the-counter pharmaceutical products. It also invests in finances of other life sciences companies with the goal of securing product distribution rights. The company focuses on a range of therapeutic areas, including oncology, inflammatory diseases, fungal infections, chronic hepatitis C, and more.
TypePublic
Founded2014
HQWestmount, CA
Websitegud-knight.com

Latest Updates

Employees (est.) (Dec 2019)719
Share Price (Jul 2021)C$5.3
Cybersecurity ratingBMore

Key People/Management at Knight Therapeutics

James C. Gale

James C. Gale

Chairman of the Board
Samira Sakhia

Samira Sakhia

President
Jonathan Ross Goodman

Jonathan Ross Goodman

Director, CEO and Founder
Amal Khouri

Amal Khouri

Vice-President, Business Development
Arvind Utchanah

Arvind Utchanah

Chief Financial Officer
Robert Lande

Robert Lande

Director
Show more

Knight Therapeutics Office Locations

Knight Therapeutics has an office in Westmount
Westmount, CA (HQ)
1055-3400 Maisonneuve Blvd W
Show all (1)

Knight Therapeutics Financials and Metrics

Knight Therapeutics Revenue

Market capitalization (15-Jul-2021)

666.6m

Closing stock price (15-Jul-2021)

5.3
Knight Therapeutics's current market capitalization is C$666.6 m.
Show all financial metrics

Knight Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

B

87/100

SecurityScorecard logo

Knight Therapeutics Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

30-39

out of 100

CSRHub logo

Knight Therapeutics Online and Social Media Presence

Embed Graph

Knight Therapeutics News and Updates

Knight Therapeutics Announces Health Canada Approval for NERLYNX® (Neratinib) to Treat HER2-Positive Metastatic Breast Cancer

MONTREAL, July 06, 2021 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD), (“Knight”) a pan-American (ex-USA) specialty pharmaceutical company, announced today that Health Canada has approved NERLYNX® (neratinib) in combination with capecitabine for the treatment of adult patients with metas…

Knight Therapeutics Announces Closing of Previously Announced Acquisition and Exclusive License to Exelon® in Canada and Latin America

MONTREAL, May 26, 2021 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight") a pan-America (ex-USA) specialty pharmaceutical company, is pleased to announce that it has completed the acquisition of the exclusive rights to manufacture, market and sell Exelon® (rivastigmine Patch, Capsu…

Knight Therapeutics Reports First Quarter 2021 Results

MONTREAL, May 14, 2021 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its first quarter ended March 31, 2021. All currency amounts are in thousands except for…

Knight Therapeutics to Acquire Regional Rights to Exelon®

MONTREAL, April 23, 2021 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight") a pan-America (ex-USA) specialty pharmaceutical company, today announced that it has entered into a definitive agreement under which Knight will acquire the exclusive rights to manufacture, market and sell …

Knight Therapeutics Reports Fourth Quarter and Year End 2020 Results

MONTREAL, March 25, 2021 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its fourth quarter and year ended December 31, 2020. All currency amounts are in thous…
Show more

Knight Therapeutics Frequently Asked Questions

  • When was Knight Therapeutics founded?

    Knight Therapeutics was founded in 2014.

  • Who are Knight Therapeutics key executives?

    Knight Therapeutics's key executives are James C. Gale, Samira Sakhia and Jonathan Ross Goodman.

  • How many employees does Knight Therapeutics have?

    Knight Therapeutics has 719 employees.

  • Who are Knight Therapeutics competitors?

    Competitors of Knight Therapeutics include Ironshore Pharmaceuticals, Chia Tai Tianqing and Eddingpharm.

  • Where is Knight Therapeutics headquarters?

    Knight Therapeutics headquarters is located at 1055-3400 Maisonneuve Blvd W, Westmount.

  • Where are Knight Therapeutics offices?

    Knight Therapeutics has an office in Westmount.

  • How many offices does Knight Therapeutics have?

    Knight Therapeutics has 1 office.